BIND Therapeutics entered a joint research and development agreement with Merck, through a subsidiary, to discover and develop nanomedicines for oncology. The collaboration will leverage BIND’s ...

If Merck opts in, it will pay BIND a fee based on a multiple of BIND's research and development expenses, plus a royalty on future product sales. Further terms of the agreement were not disclosed.